Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006)
Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in Previously Exposed Adults
Sponsor: Themis Bioscience GmbH
This PHASE2 trial investigates Chikungunya Virus Infection and is currently completed. Themis Bioscience GmbH leads this study, which shows 9 recorded versions since 2019 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2022 — Sep 2022 [monthly]
Completed PHASE2
-
Sep 2021 — Jun 2022 [monthly]
Completed PHASE2
Status: Suspended → Completed
▶ Show 4 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Aug 2019 — Dec 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2019 — Aug 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Themis Bioscience GmbH
- Walter Reed Army Institute of Research (WRAIR)
For direct contact, visit the study record on ClinicalTrials.gov .